Last Chance: Get 30 Days of MarketBeat All Access for FREE, then just $399 $199 for the year.
Start free trial
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
EXTENDED - TODAY ONLY: MarketBeat All Access For Just $399 $199 (save 50%)
Special Offer: Just $199
×
S&P 500   3,960.68 (-0.08%)
DOW   33,806.57 (-0.13%)
QQQ   282.17 (-0.19%)
AAPL   143.58 (-0.44%)
MSFT   241.88 (+0.05%)
META   110.78 (+1.84%)
GOOGL   95.59 (-0.48%)
AMZN   93.59 (-0.38%)
TSLA   182.74 (-0.10%)
NVDA   156.95 (-0.83%)
NIO   10.57 (+4.45%)
BABA   80.33 (+5.86%)
AMD   72.96 (-0.31%)
T   18.87 (+0.27%)
MU   55.67 (-0.14%)
F   13.87 (+1.02%)
DIS   95.50 (-0.20%)
AMC   7.16 (-2.32%)
PYPL   78.51 (-1.78%)
PFE   49.54 (-0.06%)
NFLX   280.82 (-0.12%)
S&P 500   3,960.68 (-0.08%)
DOW   33,806.57 (-0.13%)
QQQ   282.17 (-0.19%)
AAPL   143.58 (-0.44%)
MSFT   241.88 (+0.05%)
META   110.78 (+1.84%)
GOOGL   95.59 (-0.48%)
AMZN   93.59 (-0.38%)
TSLA   182.74 (-0.10%)
NVDA   156.95 (-0.83%)
NIO   10.57 (+4.45%)
BABA   80.33 (+5.86%)
AMD   72.96 (-0.31%)
T   18.87 (+0.27%)
MU   55.67 (-0.14%)
F   13.87 (+1.02%)
DIS   95.50 (-0.20%)
AMC   7.16 (-2.32%)
PYPL   78.51 (-1.78%)
PFE   49.54 (-0.06%)
NFLX   280.82 (-0.12%)
S&P 500   3,960.68 (-0.08%)
DOW   33,806.57 (-0.13%)
QQQ   282.17 (-0.19%)
AAPL   143.58 (-0.44%)
MSFT   241.88 (+0.05%)
META   110.78 (+1.84%)
GOOGL   95.59 (-0.48%)
AMZN   93.59 (-0.38%)
TSLA   182.74 (-0.10%)
NVDA   156.95 (-0.83%)
NIO   10.57 (+4.45%)
BABA   80.33 (+5.86%)
AMD   72.96 (-0.31%)
T   18.87 (+0.27%)
MU   55.67 (-0.14%)
F   13.87 (+1.02%)
DIS   95.50 (-0.20%)
AMC   7.16 (-2.32%)
PYPL   78.51 (-1.78%)
PFE   49.54 (-0.06%)
NFLX   280.82 (-0.12%)
S&P 500   3,960.68 (-0.08%)
DOW   33,806.57 (-0.13%)
QQQ   282.17 (-0.19%)
AAPL   143.58 (-0.44%)
MSFT   241.88 (+0.05%)
META   110.78 (+1.84%)
GOOGL   95.59 (-0.48%)
AMZN   93.59 (-0.38%)
TSLA   182.74 (-0.10%)
NVDA   156.95 (-0.83%)
NIO   10.57 (+4.45%)
BABA   80.33 (+5.86%)
AMD   72.96 (-0.31%)
T   18.87 (+0.27%)
MU   55.67 (-0.14%)
F   13.87 (+1.02%)
DIS   95.50 (-0.20%)
AMC   7.16 (-2.32%)
PYPL   78.51 (-1.78%)
PFE   49.54 (-0.06%)
NFLX   280.82 (-0.12%)
NASDAQ:BLRX

BioLineRx - BLRX Stock Forecast, Price & News

$0.70
+0.01 (+1.45%)
(As of 11/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.69
▼
$0.72
50-Day Range
$0.60
▼
$1.01
52-Week Range
$0.57
▼
$3.02
Volume
238,272 shs
Average Volume
516,107 shs
Market Capitalization
$43.06 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

BioLineRx MarketRank™ Forecast

Analyst Rating
N/A
0.00 Rating Score
Upside/​Downside
757.3% Upside
$6.00 Price Target
Short Interest
Healthy
0.42% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of BioLineRx in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.51) to ($0.53) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.46 out of 5 stars

Medical Sector

986th out of 1,038 stocks

Pharmaceutical Preparations Industry

477th out of 510 stocks

See Top Rated MarketRank™ Stocks Here
BLRX stock logo

About BioLineRx (NASDAQ:BLRX) Stock

BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials for the treatment of metastatic pancreatic adenocarcinoma patients, and Phase 1b clinical trials in patients with acute respiratory distress syndrome secondary to COVID-19 and other respiratory viral infections, as well as for the treatment of solid tumors and acute myeloid leukemia. It is also developing AGI-134, an immuno-oncology agent, which is in Phase 1/2a clinical trials for the treatment of solid tumors; and BL-5010, a customized, proprietary, pen-like applicator for the non-surgical removal of skin lesions. The company has collaboration agreement with MSD for the cancer immunotherapy field; MD Anderson Cancer Center to investigate the combination of Motixafortide with KEYTRUDA (pembrolizumab) in pancreatic cancer; and licensing arrangement with Perrigo Company plc for over-the-counter sale of BL-5010. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

BLRX Stock News Headlines

November 20, 2022 | americanbankingnews.com
FY2022 EPS Estimates for BioLineRx Ltd. Lifted by Analyst (NASDAQ:BLRX)
November 15, 2022 | finance.yahoo.com
BioLineRx Reports Third Quarter 2022 Financial Results and Recent Corporate and Portfolio Updates
November 10, 2022 | finance.yahoo.com
BioLineRx Announces U.S. FDA Acceptance of New Drug Application for APHEXDA® (motixafortide) in Stem Cell Mobilization
November 10, 2022 | finance.yahoo.com
BioLineRx to Report Third Quarter 2022 Results on November 15, 2022
November 4, 2022 | finance.yahoo.com
BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification
November 3, 2022 | finance.yahoo.com
BioLineRx Announces Presentations on Cost-Effectiveness of Motixafortide in Multiple Myeloma and Program for Potential Motixafortide Indication Expansion in Gene Therapy at the 64th American Society of Hematology (ASH) Annual Meeting
November 2, 2022 | finance.yahoo.com
BLRX: Cast Off the Bowlines: Aphexda Commercialization
September 28, 2022 | finance.yahoo.com
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization - Yahoo Finance
September 27, 2022 | finance.yahoo.com
BioLineRx Announces U.S. Commercialization Plan for APHEXDA (Motixafortide) in Stem Cell Mobilization
September 21, 2022 | streetinsider.com
Form 6-K BioLineRx Ltd. For: Sep 21 - StreetInsider.com
September 20, 2022 | businesswire.com
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in BioLineRx Ltd. with Losses of $100000 to Contact the Firm - Business Wire
September 19, 2022 | finance.yahoo.com
BioLineRx Announces $15 Million Registered Direct Offering - Yahoo Finance
September 19, 2022 | businesswire.com
EQUITY ALERT: Rosen Law Firm Encourages BioLineRx Ltd. Investors to Inquire About Securities Class Action Investigation – BLRX - Business Wire
September 19, 2022 | seekingalpha.com
BioLineRx stock slips on $15M securities offering - Seeking Alpha
September 19, 2022 | finance.yahoo.com
BioLineRx Announces $15 Million Registered Direct Offering
September 15, 2022 | streetinsider.com
BioLineRx (BLRX) Enters $40M Non-Dilutive Debt Financing Agreement with Kreos Capital - StreetInsider.com
September 15, 2022 | finance.yahoo.com
BioLineRx Secures $40M In Debt Financing To Fund Commercialization Of Stem Cell Mobilization For Blood Cancer
September 15, 2022 | finance.yahoo.com
BioLineRx Announces $40 Million Non-Dilutive Debt Financing Agreement with Kreos Capital
September 14, 2022 | finance.yahoo.com
New Therapeutics Options in Pancreatic Ductal Adenocarcinoma Pipeline as 40+ Key Companies are Working on Drug Profiles | DelveInsight - Yahoo Finance
September 14, 2022 | finance.yahoo.com
BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization - Yahoo Finance
September 13, 2022 | benzinga.com
BioLine Rx (NASDAQ:BLRX) – BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixa - Benzinga
September 12, 2022 | benzinga.com
BioLine Rx (NASDAQ:BLRX) – BioLineRx Announces Submission Of New Drug Application To FDA For Motixafortid - Benzinga
September 12, 2022 | nasdaq.com
BioLineRx Announces Submission Of Its First NDA - Quick Facts
September 12, 2022 | finance.yahoo.com
BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization
September 2, 2022 | finance.yahoo.com
Global Actinic Keratosis Treatment Market to Reach $10.08 Billion by 2027 at a CAGR of 10.61% - Yahoo Finance
See More Headlines
Receive BLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioLineRx and its competitors with MarketBeat's FREE daily newsletter.

BLRX Company Calendar

Last Earnings
12/08/2021
Today
11/29/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/15/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLRX
CUSIP
N/A
CIK
1498403
Web
www.biolinerx.com
Phone
(728) 642-9100
Fax
972-8642-9101
Employees
38
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+757.3%
Consensus Rating
N/A
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.49)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-27,050,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-38.63%
Return on Assets
-30.78%

Debt

Debt-to-Equity Ratio
0.15
Current Ratio
7.12
Quick Ratio
7.12

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.43 per share
Price / Book
0.49

Miscellaneous

Outstanding Shares
61,520,000
Free Float
60,847,000
Market Cap
$43.06 million
Optionable
Not Optionable
Beta
1.86

Key Executives

  • Mr. Philip A. Serlin CPA (Age 62)
    M.B.A., CPA, MBA, Chief Exec. Officer
    Comp: $644k
  • Ms. Mali Zeevi CPA (Age 46)
    CPA, Chief Financial Officer
    Comp: $391k
  • Dr. Ella Sorani (Age 54)
    Chief Devel. Officer
    Comp: $414k
  • Dr. Abi Vainstein-Haras M.D. (Age 47)
    Chief Medical Officer
    Comp: $391k
  • Advocate Norman Kotler (Age 70)
    Internal Enforcement Officer, Gen. Counsel and Corp. Sec.
  • Ms. Liron Shemesh-Darvish M.B.A.
    Ph.D., Sr. Director & Head of Preclinical Devel.
  • Ms. Jael Birenberg M.Sc.
    Sr. Director & Head of RA, QA and PhV
  • Ms. Tsipi Keren-Lehrer B.Sc.
    L.L.B., Head of BD & Strategic Advisor
  • Ms. Holly W. May M.B.A.
    Pres of BioLineRx USA
  • Mr. Raziel Fried
    Treasurer & Budgetary Control Director

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BLRX Stock - Frequently Asked Questions

What is BioLineRx's stock price forecast for 2023?

0 analysts have issued 1 year target prices for BioLineRx's shares. Their BLRX share price forecasts range from $6.00 to $6.00. On average, they anticipate the company's stock price to reach $6.00 in the next year. This suggests a possible upside of 757.3% from the stock's current price.
View analysts price targets for BLRX or view top-rated stocks among Wall Street analysts.

How have BLRX shares performed in 2022?

BioLineRx's stock was trading at $2.04 at the beginning of the year. Since then, BLRX shares have decreased by 65.7% and is now trading at $0.6999.
View the best growth stocks for 2022 here.

Are investors shorting BioLineRx?

BioLineRx saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 260,200 shares, an increase of 7.3% from the October 31st total of 242,500 shares. Based on an average trading volume of 363,300 shares, the short-interest ratio is presently 0.7 days.
View BioLineRx's Short Interest.

When is BioLineRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 15th 2023.
View our BLRX earnings forecast.

How were BioLineRx's earnings last quarter?

BioLineRx Ltd. (NASDAQ:BLRX) released its quarterly earnings results on Wednesday, December, 8th. The biotechnology company reported ($0.15) earnings per share for the quarter, beating analysts' consensus estimates of ($0.16) by $0.01.

What other stocks do shareholders of BioLineRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLineRx investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Zosano Pharma (ZSAN), KushCo (KSHB), Aeterna Zentaris (AEZS), CNBX Pharmaceuticals (CNBX), Pennsylvania Real Estate Investment Trust (PEI), Savara (SVRA), Bionano Genomics (BNGO) and Gran Tierra Energy (GTE).

What is BioLineRx's stock symbol?

BioLineRx trades on the NASDAQ under the ticker symbol "BLRX."

Who are BioLineRx's major shareholders?

BioLineRx's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Altium Capital Management LP (6.74%), Armistice Capital LLC (4.55%), Renaissance Technologies LLC (0.11%), Apollon Wealth Management LLC (0.08%), PVG Asset Management Corp (0.10%) and Virtu Financial LLC (0.08%).

How do I buy shares of BioLineRx?

Shares of BLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is BioLineRx's stock price today?

One share of BLRX stock can currently be purchased for approximately $0.70.

How much money does BioLineRx make?

BioLineRx (NASDAQ:BLRX) has a market capitalization of $43.06 million. The biotechnology company earns $-27,050,000.00 in net income (profit) each year or ($0.49) on an earnings per share basis.

How can I contact BioLineRx?

BioLineRx's mailing address is 2 HAMA-AYAN STREET, MODI-IN L3, 7177871. The official website for the company is www.biolinerx.com. The biotechnology company can be reached via phone at (728) 642-9100, via email at ir@biolinerx.com, or via fax at 972-8642-9101.

This page (NASDAQ:BLRX) was last updated on 11/29/2022 by MarketBeat.com Staff